Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 1
1963 4
1964 4
1965 5
1966 1
1967 2
1968 1
1973 1
1975 1
1976 3
1983 1
1994 1
2004 1
2006 3
2007 1
2009 2
2010 3
2011 5
2012 2
2013 3
2014 3
2015 5
2016 2
2017 1
2018 2
2019 2
2020 4
2021 4
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Settergren M, Sjöstrand C, Roine RO, Hildick-Smith D, Spence JD, Thomassen L; Gore REDUCE Clinical Study Investigators. Søndergaard L, et al. N Engl J Med. 2017 Sep 14;377(11):1033-1042. doi: 10.1056/NEJMoa1707404. N Engl J Med. 2017. PMID: 28902580 Free article. Clinical Trial.
CANDIDA CHEILITIS.
JANSEN GT, DILLAHA CJ, HONEYCUTT WM. JANSEN GT, et al. Among authors: honeycutt wm. Arch Dermatol. 1963 Sep;88:325-9. doi: 10.1001/archderm.1963.01590210083013. Arch Dermatol. 1963. PMID: 14043627 No abstract available.
Scabies.
Honeycutt WM. Honeycutt WM. Compr Ther. 1976 May;2(5):71-4. Compr Ther. 1976. PMID: 58755 No abstract available.
SHIGELLOSIS.
HONEYCUTT WM, DILLAHA CJ, JANSEN GT. HONEYCUTT WM, et al. J Ark Med Soc. 1964 Nov;61:193-4. J Ark Med Soc. 1964. PMID: 14218577 No abstract available.
Further studies with topical 5-fluorouracil.
Dillaha CJ, Jansen GT, Honeycutt WM, Holt GA. Dillaha CJ, et al. Among authors: honeycutt wm. Arch Dermatol. 1965 Oct;92(4):410-7. Arch Dermatol. 1965. PMID: 5835333 No abstract available.
Selective cytotoxic effect of topical 5-fluorouracil.
Dillaha CJ, Jansen GT, Honeycutt WM, Bradford AC. Dillaha CJ, et al. Among authors: honeycutt wm. Arch Dermatol. 1983 Sep;119(9):774-83. Arch Dermatol. 1983. PMID: 6614965 Clinical Trial.
68 results